Serina Therapeutics Announces FDA Clearance of IND Application for SER-252 for the Treatment of Advanced Parkinson’s disease
Rhea-AI Summary
Serina Therapeutics (NYSE American: SER) announced FDA clearance of its IND application for SER-252, enabling initiation of site‑level and regulatory activities to start a planned Phase 1b registrational study in advanced Parkinson’s disease. The company noted prior FDA feedback and alignment on a 505(b)(2) NDA pathway.
Positive
- FDA cleared IND for SER-252, allowing Phase 1b registrational study initiation
- FDA provided written feedback supporting the proposed registrational trial design
- Regulatory alignment on a 505(b)(2) NDA pathway offers a defined development route
Negative
- No clinical outcome or efficacy data reported; trial initiation only enables future data generation
- Planned Phase 1b study start remains subject to site activation timelines and further regulatory actions
News Market Reaction – SER
In the Jan 29 session, SER gained 30.15%, reflecting a significant positive market reaction. Argus tracked a peak move of +90.0% during that session. Our momentum scanner triggered 30 alerts that day, indicating elevated trading interest and price volatility. Trading volume was exceptionally heavy at 152.9x the daily average, suggesting very strong buying interest.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jan 15 | Listing deficiency notice | Negative | +0.8% | NYSE American notified Serina of stockholders’ equity deficiency and cure timeline. |
| Dec 11 | Leadership appointment | Positive | -2.2% | Appointed VP, Head of Chemistry to support POZ platform and SER-252 development. |
| Dec 10 | Clinical hold response | Positive | -3.0% | Submitted complete response to FDA clinical hold letter for SER-252, revising protocol. |
| Nov 13 | Earnings and financing | Negative | -2.5% | Reported Q3 2025 results, clinical hold risk, and detailed limited cash plus new financing. |
| Nov 03 | FDA clinical hold | Negative | -6.4% | FDA placed clinical hold on SER-252 IND requesting more data on a formulation excipient. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent news often led to price declines, particularly around regulatory setbacks and financing, with occasional divergence when negative fundamentals did not trigger selling.
Over the past few months, Serina’s news flow focused on SER-252 regulatory interactions and financial pressures. On Nov 3, 2025, the FDA placed SER-252 on clinical hold, followed by a complete response filing on Dec 9, 2025. An 8-K in mid-January 2026 detailed NYSE American equity deficiency concerns tied to $1.6M stockholders’ equity. Leadership strengthening and financing updates supported the SER-252 program. Today’s IND clearance directly follows this clinical hold sequence and aligns with prior FDA 505(b)(2) discussions.
Key Terms
investigational new drug (ind) regulatory
phase 1b medical
505(b)(2) nda pathway regulatory
registrational medical
parkinson’s disease medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
- Phase 1b clinical site start-up and regulatory activities in Australia underway to support the global registrational program -
HUNTSVILLE, AL, Jan. 28, 2026 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina” or the "Company") (NYSE American: SER), a clinical-stage biotechnology company advancing drug candidates enabled by its proprietary POZ PlatformTM drug optimization technology, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for SER-252, an investigational therapy for advanced Parkinson’s disease.
The IND clearance allows Serina to proceed with regulatory and site-level activities to support initiation of a planned Phase 1b registrational clinical study evaluating SER-252 in patients with advanced Parkinson’s disease.
“FDA clearance of the IND is a major milestone for Serina and underscores the promise of the SER-252 program,” said Steve Ledger, Chief Executive Officer of Serina Therapeutics. “As we initiate our registrational study, we will begin generating meaningful clinical data for SER-252 in patients with advanced Parkinson’s disease. With FDA alignment on a registrational development strategy under a 505(b)(2) NDA pathway, we believe SER-252 has a clear and efficient path forward toward addressing a significant unmet medical need.”
As previously disclosed, Serina has engaged in multiple regulatory interactions with the FDA regarding the SER-252 program, including receipt of written FDA feedback supporting the proposed registrational clinical trial design under a 505(b)(2) NDA pathway.
About Serina Therapeutics
Serina is a clinical-stage biotechnology company developing a pipeline of wholly owned drug product candidates to treat neurological diseases and other indications. Serina’s POZ PlatformTM provides the potential to improve the integrated efficacy and safety profile of multiple modalities including small molecules, RNA-based therapeutics and antibody-based drug conjugates (ADCs). Serina is headquartered in Huntsville, Alabama on the campus of the HudsonAlpha Institute of Biotechnology.
About the POZ PlatformTM
Serina’s proprietary POZ technology is based on a synthetic, water soluble, low viscosity polymer called poly(2-oxazoline). Serina’s POZ technology is engineered to provide greater control in drug loading and more precision in the rate of release of attached drugs delivered via subcutaneous injection. The therapeutic agents in Serina’s product candidates are typically well-understood and marketed drugs that are effective but are limited by pharmacokinetic profiles that can include toxicity, side effects and short half-life. Serina believes that by using POZ technology, drugs with narrow therapeutic windows can be designed to maintain more desirable and stable levels in the blood.
Serina’s POZ platform delivery technology has potential for use across a broad range of payloads and indications. Serina intends to advance additional applications of the POZ platform via out-licensing, co-development, or other partnership arrangements, including the non-exclusive license agreement with Pfizer, Inc. to use Serina’s POZ polymer technology for use in lipid nanoparticle drug (LNP) delivery formulations.
About SER-252 (POZ-apomorphine)
SER 252 is an investigational apomorphine therapy developed with Serina’s POZ platform and designed to provide continuous dopaminergic stimulation (CDS). CDS has been shown to reduce the severity of levodopa-related motor complications (dyskinesia) in Parkinson’s disease. Preclinical studies support the potential of SER 252 to provide CDS without skin reactions.
Cautionary Statement Regarding Forward-Looking Statement
References in this Report to “Serina,” “the Company,” “we” or “us” refer to Serina Therapeutics, Inc. This release contains forward-looking statements within the meaning of federal securities laws. All statements that are not historical fact, including statements about Serina’s planned clinical programs, including timing for first-patient-in and resolution of the clinical hold and customary regulatory and ethics approvals, the potential of Serina’s POZ polymer technology, are forward-looking statements that involve substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These statements are based on management’s current expectations, plans, beliefs or forecasts for the future, and are subject to uncertainty and changes in circumstances. Undue reliance should not be placed on these forward-looking statements which speak only as of the date they are made, and the facts and assumptions underlying these statements may change.
Actual results may differ materially from those projected in such statements due to a variety of important factors including, among other things, the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as the possibility of unfavorable new clinical data and further analyses of existing clinical data; Serina’s ability to continue as a going concern; the risk that clinical trial data are subject to differing interpretations and assessments by regulatory authorities; whether regulatory authorities will be satisfied with the design of and results from our clinical studies; whether and when any applications may be filed for any drug or vaccine candidates in any jurisdictions; whether and when regulatory authorities may approve any potential applications that may be filed for any drug or vaccine candidates in any jurisdictions, which will depend on a myriad of factors, including making a determination as to whether the product’s benefits outweigh its known risks and determination of the product’s efficacy and, if approved, whether any such drug or vaccine candidates will be commercially successful; decisions by regulatory authorities impacting labeling, manufacturing processes, safety and/or other matters that could affect the availability or commercial potential of any drug or vaccine candidates; and competitive developments. These risks as well as other risks are more fully discussed in the company’s Annual Report on Form 10-K for the year ended December 31, 2024, and the company’s other periodic reports and documents filed from time to time with the SEC. The information contained in this release is as of the date hereof, and Serina assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.
For inquiries, please contact:
Stefan Riley
sriley@serinatherapeutics.com
(256) 327-9630
